Anesthesiology and Pain Medicine

Published by: Kowsar

Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis

Masoumeh Nouri 1 , Arezoo Ahmadi 2 , Farhad Etezadi 2 , Elchin Barzegar 1 and Mojtaba Mojtahedzadeh 1 , *
Authors Information
1 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Anesthesiology and Pain Medicine: April 01, 2016, 6 (2); e33780
  • Published Online: April 2, 2016
  • Article Type: Research Article
  • Received: October 12, 2015
  • Revised: November 20, 2015
  • Accepted: January 6, 2016
  • DOI: 10.5812/aapm.33780

To Cite: Nouri M, Ahmadi A, Etezadi F, Barzegar E, Mojtahedzadeh M. Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis, Anesth Pain Med. 2016 ; 6(2):e33780. doi: 10.5812/aapm.33780.

Abstract
Copyright © 2016, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Cornet AD, Smit EG, Beishuizen A, Groeneveld AB. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost. 2007; 98(3): 579-86[PubMed]
  • 2. Lorente L, Martin MM, Borreguero-Leon JM, Sole-Violan J, Ferreres J, Labarta L, et al. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients. Thromb Res. 2014; 134(1): 182-6[DOI][PubMed]
  • 3. Peres Wingeyer SD, Cunto ER, Nogueras CM, San Juan JA, Gomez N, de Larranaga GF. Biomarkers in sepsis at time zero: intensive care unit scores, plasma measurements and polymorphisms in Argentina. J Infect Dev Ctries. 2012; 6(7): 555-62[PubMed]
  • 4. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012; 129(3): 290-5[DOI][PubMed]
  • 5. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006; 84(5): 398-405[DOI][PubMed]
  • 6. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011; 22(6): 999-1006[DOI][PubMed]
  • 7. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009; 102(5): 823-8[DOI][PubMed]
  • 8. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol. 2009; 6(4): 281-9[PubMed]
  • 9. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008; 36(11): 2973-9[DOI][PubMed]
  • 10. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(2): 580-637[DOI][PubMed]
  • 11. Anastase-Ravion S, Blondin C, Cholley B, Haeffner-Cavaillon N, Castellot JJ, Letourneur D. Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res A. 2003; 66(2): 376-84[DOI][PubMed]
  • 12. Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014; 18(5): 563[DOI][PubMed]
  • 13. Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015; 43(3): 511-8[DOI][PubMed]
  • 14. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014; 77: 3-11[DOI][PubMed]
  • 15. Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart A. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation. 2001; 103(24): 2994-3018[PubMed]
  • 16. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest P. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl)-43S[DOI][PubMed]
  • 17. Jaimes F, De la Rosa G, Arango C, Fortich F, Morales C, Aguirre D, et al. A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308]. Trials. 2006; 7: 19[DOI][PubMed]
  • 18. Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014; 18(1)[DOI][PubMed]
  • 19. Liu XL, Wang XZ, Liu XX, Hao D, Jaladat Y, Lu F, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Ther Med. 2014; 7(3): 604-8[DOI][PubMed]
  • 20. Shapiro NI, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care. 2010; 14(5)[DOI][PubMed]
  • 21. Aydogdu M, Gursel G, Sancak B, Yeni S, Sari G, Tasyurek S, et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and Cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers. 2013; 34(4): 237-46[DOI][PubMed]
  • 22. Vanmassenhove J, Glorieux G, Lameire N, Hoste E, Dhondt A, Vanholder R, et al. Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis. BMC Nephrol. 2015; 16: 18[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments